AstraZeneca says its trial drug for thyroid cancer granted US FDA orphan drug designation
May 12, 2016Research and Development, Sales and Marketing AstraZeneca, Orphan Drug Designation, US FDA, drug trial, regulation
AstraZeneca (LSE: AZN) on Thursday said the US Food and Drug Administration (FDA) has granted Orphan Drug Designation its trial …
Nice recommends two blood tests to rule out pre-eclampsia in pregnant women
May 11, 2016Medical Communications, Sales and Marketing NICE, Roche, regulation
The National Institute for Health and Care Excellence (Nice) has backed two blood tests to help rule-out a complication in …
Nice backs GSK’s lupus drug Benlysta
May 11, 2016Research and Development, Sales and Marketing GSK, NHS, NICE, regulation
The National Institute for Health and Care Excellence (Nice) has backed GlaxoSmithKline’s (LSE: GSK) Benlysta (belimumab) to treat lupus. The …
Gilead’s Sovaldi gets Indian patent; critics call it “major blow” to patient access
May 11, 2016Manufacturing and Production, Research and Development, Sales and Marketing India, harm, hepatitis, patent, patient access, sovaldi
Gilead has been granted a patent for its hepatitis C drug, Sovaldi (sofosbuvir), in India which has sparked dismay among …
Santen Pharmaceutical says eye allergy drug meets primary endpoints in Phase III trials
May 11, 2016Research and Development, Sales and Marketing Eye Allergy, Santen Pharmaceutical, drug trial, phase III
Santen Pharmaceutical said late stage trials for its drug to treat an allergic eye condition in children met its primary …
Allergan to buy back $10 billion of stock, Q1 earnings rise
May 11, 2016Research and Development, Sales and Marketing Allergan, Buy Back, Financial, Q1, earnings, results, revenue
Botox-maker Allergan (NYSE: AGN) said it plans to buy back as much as $10 billion in stock after completing the …
FDA expands Imbruvica label with new survival data
May 11, 2016Research and Development, Sales and Marketing AbbVie, FDA, Janssen, data, efficacy, expanded, imbruvica, label, late stage, phase III
The US Food and Drug Administration (FDA) has expanded the label of Imbruvica (ibrutinib) to include the data from recent …
Baxalta sues Chugai for haemophilia drug patent breach
May 11, 2016Research and Development Baxalta, Chugai, breach, court, haemophilia, infringe, infringement, patent, sue, suing
Baxalta has taken Chugai Pharmaceuticals to the Tokyo district court, claiming that the Japanese company has infringed upon its patent …
Incyte acquires Ariad’s European operations in $140 million deal
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ariad, Incyte, Operations, buy out, european, iclusig, leukaemia, out-license
Incyte (NASDAQ: INCY) has entered into an agreement with Ariad Pharmaceuticals (NASDAQ: ARIA) that will see the company acquire Ariad’s …
Cell Therapy signs £12.5 million licensing deal with Daiichi Sankyo for heart failure treatment
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Daiichi Sankyo, Deals, cell therapy, heart failure, licensing
UK-based Cell Therapy on Tuesday said it has signed a £12.5 million licensing deal with Japan’s Daiichi Sankyo (TYO: 4568) …
Medivation maybe mulling sale as bidding race heats up – Reports
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Deals, M&A, MA, Medivation, Pfizer, Sanofi
Cancer drugmaker Medivation (Nasdaq: MDVN) is evaluating a potential sale following the recent string of offers from big pharma firms, …
Takeda secures $38 million grant to develop affordable polio vaccine
May 10, 2016Manufacturing and Production, Research and Development Bill and Melinda Gates Foundation, Gates Foundation, Takeda, Vaccine, access, developing countries, grant, polio
Takeda Pharmaceuticals has received a $38 million grant from the Bill and Melinda Gates Foundation to develop a low-cost polio …
Scottish Medicines Consortium does not back Vertex’ cystic fibrosis drugs Orkambi, Kalydeco
May 10, 2016Manufacturing and Production, Research and Development Kalydeco, Orkambi, SMC, Vertex Pharma, cystic fibrosis, regulation
The Scottish Medicines Consortium did not back two cystic fibrosis therapies from Vertex Pharmaceutical (Nasdaq: VRTX). SMC did not recommend …
Second child cleared of leukaemia after Cellectis T-cell treatment
May 10, 2016Manufacturing and Production, Research and Development cellecits, childhood, children, designer cells, leukaemia, rare, t cells, t-cells
A targeted T-cell oncology therapy has successfully treated a second baby with aggressive leukaemia who has remained in remission after …
China evaluating investigations into pharma firms to take on drug pricing issue
May 9, 2016Business Services, Research and Development, Sales and Marketing China, France, G7, regulation
Lawmakers globally have acknowledged the concerns over unbridled drug costs as regulators stress the need for a more open debate …
UK pharma would benefit by remaining in EU, says ABPI
May 9, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Andrew Witty, EU, brexit, letter, observer, pascal soriot, remain, stay
With the EU vote approaching, the Association of the British Pharmaceutical Industry (ABPI) has brought together 93 signatories, including the …
Focus: Governments evaluate policies, reforms as drug pricing debate rages on
May 9, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
By Anjali Shukla Lawmakers in France are set to urge the leaders of G7 countries to put in place guidelines …
Chiesi set to acquire Medicine Co cardiovascular assets, say reports
May 9, 2016Sales and Marketing Chiesi, assets, cardiovascular, medicine co
Italian pharmaceutical company Chiesi are set to expand their global footprint as it nears an agreement to acquire Medicines Co’s …
Endo shares plunge almost 40% as company cuts FY outlook
May 9, 2016Sales and Marketing Endo International, earnings, outlook, revenue
Shares in Endo International (Nasdaq: ENDP) plunged to close down nearly 40% after the company cut its full-year earnings forecast …
BTG acquires promising oncology pipeline in Galil Medical takeover
May 9, 2016Manufacturing and Production, Research and Development, Sales and Marketing $84 million, BTG, cryoablation, galil medical, oncology, takeover
BTG (LSE: BTG) has announced that is has agreed to acquire Galil Medical, a leading provider of cryoablation products for …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
